Vaccine-induced measles virus-specific T cells do not prevent infection or disease but facilitate subsequent clearance of viral RNA

mBio

Volumn 5, Issue 2, 2014, Pages

  Lin, Wen Hsuan W ^a,c   Pan, Chien Hsiung ^a,d   Adams, Robert J ^b   Laube, Beth L ^b   Griffin, Diane E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Pediatrics Johns Hopkins University School of Medicine ^*  (United States)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MEASLES VACCINE; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; MEASLES; MEASLES VIRUS; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; RASH; RHESUS MONKEY; SINGLE DRUG DOSE; VIRAL CLEARANCE; VIREMIA;

ADMINISTRATION, INHALATION; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELLS, CULTURED; CYTOKINES; MACACA MULATTA; MEASLES; MEASLES VACCINE; MEASLES VIRUS; RNA, VIRAL; T-LYMPHOCYTES; VACCINES, ATTENUATED;

EID: 84899789460     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01047-14     Document Type: Article

References (51)

1. Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, Plotkin SA. 2013. Accelerating next-generation vaccine development for global disease prevention. Science 340:1232910. http://dx.doi.org/10.1126/science.1232910.
2. Plotkin SA. 2013. Complex correlates of protection after vaccination. Clin. Infect. Dis. 56:1458-1465. http://dx.doi.org/10.1093/cid/cit048.
3. Robinson HL, Amara RR. 2005. T cell vaccines for microbial infections. Nat. Med. 11:S25-S32. http://dx.doi.org/10.1038/nm1212.
4. Swadling L, Klenerman P, Barnes E. 2013. Ever closer to a prophylactic vaccine for HCV. Expert Opin. Biol. Ther. 13:1109-1124. http:// dx.doi.org/10.1517/14712598.2013.791277.
5. Schiffner T, Sattentau QJ, Dorrell L. 2013. Development of prophylactic vaccines against HIV-1. Retrovirology 10:72. http://dx.doi.org/10.1186/ 1742-4690-10-72.
6. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M, Lifson JD, Picker LJ. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527. http://dx.doi.org/10.1038/nature10003.
7. Plotkin SA. 2010. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17:1055-1065. http://dx.doi.org/10.1128/CVI.00131-10.
8. Lin WH, Kouyos RD, Adams RJ, Grenfell BT, Griffin DE. 2012. Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proc. Natl. Acad. Sci. U. S. A. 109:14989-14994. http:// dx.doi.org/10.1073/pnas.1211138109.
9. Hirsch RL, Griffin DE, Johnson RT, Cooper SJ, Lindo de Soriano I, Roedenbeck S, Vaisberg A. 1984. Cellular immune responses during complicated and uncomplicated measles virus infections of man. Clin. Immunol. Immunopathol. 31:1-12. http://dx.doi.org/10.1016/0090-1229(84)90184-3.
10. Tamashiro VG, Perez HH, Griffin DE. 1987. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Pediatr. Infect. Dis. J. 6:451-454. http://dx.doi.org/10.1097/00006454-198705000-00007.
11. Von Pirquet C. 1908. Verhalten der kutanen tuberkulin-reaktion wahrend der Masern. Deutsch. Med. Wochenschr. 34:1297-1300. http:// dx.doi.org/10.1055/s-0028-1135624.
12. Panum P. 1938. Observations made during the epidemic of measles on the Faroe Islands in the year 1846. Med. Classics 3:829-886.
13. Lievano F, Galea SA, Thornton M, Wiedmann RT, Manoff SB, Tran TN, Amin MA, Seminack MM, Vagie KA, Dana A, Plotkin SA. 2012. Measles, mumps, and rubella virus vaccine (M-M-RII): a review of 32 years of clinical and postmarketing experience. Vaccine 30:6918-6926. http://dx.doi.org/10.1016/j.vaccine.2012.08.057.
14. Fontana JM, Bankamp B, Bellini WJ, Rota PA. 2008. Regulation of interferon signaling by the C and V proteins from attenuated and wildtype strains of measles virus. Virology 374:71-81. http://dx.doi.org/ 10.1016/j.virol.2007.12.031.
15. Graves M, Griffin DE, Johnson RT, Hirsch RL, de Soriano IL, Roedenbeck S, Vaisberg A. 1984. Development of antibody to measles virus polypeptides during complicated and uncomplicated measles virus infections. J. Virol. 49:409-412.
16. Ota MO, Ndhlovu Z, Oh S, Piyasirisilp S, Berzofsky JA, Moss WJ, Griffin DE. 2007. Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination. J. Infect. Dis. 195:1799-1807. http://dx.doi.org/ 10.1086/518006.
17. van Els CA, Nanan R. 2002. T cell responses in acute measles. Viral Immunol. 15:435-450. http://dx.doi.org/10.1089/088282402760312322.
18. Jaye A, Herberts CA, Jallow S, Atabani S, Klein MR, Hoogerhout P, Kidd M, van Els CA, Whittle HC. 2003. Vigorous but short-term gamma interferon T-cell responses against a dominant HLA-A*02-restricted measles virus epitope in patients with measles. J. Virol. 77:5014-5016. http:// dx.doi.org/10.1128/JVI.77.8.5014-5016.2003.
19. de Swart RL, Yüksel S, Langerijs CN, Muller CP, Osterhaus AD. 2009. Depletion of measles virus glycoprotein-specific antibodies from human sera reveals genotype-specific neutralizing antibodies. J. Gen. Virol. 90: 2982-2989. http://dx.doi.org/10.1099/vir.0.014944-0.
20. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. 1990. Measles antibody: reevaluation of protective titers. J. Infect. Dis. 162:1036-1042. http://dx.doi.org/10.1093/infdis/ 162.5.1036.
21. Ruckdeschel JC, Graziano KD, Mardiney MR, Jr. 1975. Additional evidence that the cell-associated immune system is the primary host defense against measles (rubeola). Cell. Immunol. 17:11-18. http:// dx.doi.org/10.1016/S0008-8749(75)80002-5.
22. Guidotti LG, Chisari FV. 2001. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19: 65-91. http://dx.doi.org/10.1146/annurev.immunol.19.1.65.
23. Binder GK, Griffin DE. 2001. Interferon-__mediated site specific clearance of alphavirus from CNS neurons. Science 293:303-306. http:// dx.doi.org/10.1126/science.1059742.
24. Topham DJ, Tripp RA, Doherty PC. 1997. CD8+ T cells clear influenza virus by perforin or fas-dependent processes. J. Immunol. 159:5197-5200.
25. Walker BD, Burton DR. 2008. Toward an AIDS vaccine. Science 320: 760-764. http://dx.doi.org/10.1126/science.1152622.
26. Simmonds P. 2004. Genetic diversity and evolution of hepatitis C virus-15 years on. J. Gen. Virol. 85:3173-3188. http://dx.doi.org/10.1099/ vir.0.80401-0.
27. Ndung'u T, Weiss RA. 2012. On HIV diversity. AIDS 26:1255-1260. http://dx.doi.org/10.1097/QAD.0b013e32835461b5.
28. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. 2013. Antibodies in HIV-1 vaccine development and therapy. Science 341:1199-1204. http://dx.doi.org/10.1126/science.1241144.
29. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. 1977. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91:715-718. http://dx.doi.org/10.1016/S0022-3476(77)81021-4.
30. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. 1998. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280:527-532. http:// dx.doi.org/10.1001/jama.280.6.527.
31. Nair N, Gans H, Lew-Yasukawa L, Long-Wagar AC, Arvin A, Griffin DE. 2007. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J. Infect. Dis. 196:1339-1345. http://dx.doi.org/10.1086/522519.
32. Lin WH, Griffin DE, Rota PA, Papania M, Cape SP, Bennett D, Quinn B, Sievers RE, Shermer C, Powell K, Adams RJ, Godin S, Winston S. 2011. Successful respiratory immunization with dry powder liveattenuated measles virus vaccine in rhesus macaques. Proc. Natl. Acad. Sci. U. S. A. 108:2987-2992. http://dx.doi.org/10.1073/pnas.1017334108.
33. Bouche FB, Ertl OT, Muller CP. 2002. Neutralizing B cell response in measles. Viral Immunol. 15:-451-471. http://dx.doi.org/10.1089/ 088282402760312331.
34. Ryon JJ, Moss WJ, Monze M, Griffin DE. 2002. Functional and phenotypic changes in circulating lymphocytes from hospitalized Zambian children with measles. Clin. Diagn. Lab. Immunol. 9:994-1003. http:// dx.doi.org/10.1128/CDLI.9.5.994-1003.2002.
35. Permar SR, Moss WJ, Ryon JJ, Monze M, Cutts F, Quinn TC, Griffin DE. 2001. Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. J. Infect. Dis. 183:532-538. http://dx.doi.org/10.1086/ 318533.
36. Riddell MA, Moss WJ, Hauer D, Monze M, Griffin DE. 2007. Slow clearance of measles virus RNA after acute infection. J. Clin. Virol. 39: 312-317. http://dx.doi.org/10.1016/j.jcv.2007.05.006.
37. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. 2007. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J. Virol. 81:8468-8476. http://dx.doi.org/10.1128/JVI.00228-07.
38. Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, Robinson HL, Lennox J, Amara RR. 2007. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J. Virol. 81:12071-12076. http://dx.doi.org/ 10.1128/JVI.01261-07.
39. Seder RA, Darrah PA, Roederer M. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8:247-258. http://dx.doi.org/10.1038/nri2274.
40. Low N, Kraemer S, Schneider M, Restrepo AM. 2008. Immunogenicity and safety of aerosolized measles vaccine: systematic review and metaanalysis. Vaccine 26:383-398. http://dx.doi.org/10.1016/ j.vaccine.2007.11.010.
41. de Swart RL, LiCalsi C, Quirk AV, van Amerongen G, Nodelman V, Alcock R, Yüksel S, Ward GH, Hardy JG, Vos H, Witham CL, Grainger CI, Kuiken T, Greenspan BJ, Gard TG, Osterhaus AD. 2007. Measles vaccination of macaques by dry powder inhalation. Vaccine 25: 1183-1190. http://dx.doi.org/10.1016/j.vaccine.2006.10.019.
42. Polack FP, Auwaerter PG, Lee SH, Nousari HC, Valsamakis A, Leiferman KM, Diwan A, Adams RJ, Griffin DE. 1999. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 5:629-634. http://dx.doi.org/10.1038/9473.
43. Hoffman SJ, Polack FP, Hauer DA, Singh M, Billeter MA, Adams RJ, Griffin DE. 2003. Vaccination of rhesus macaques with a recombinant measles virus expressing interleukin-12 alters humoral and cellular immune responses. J. Infect. Dis. 188:1553-1561. http://dx.doi.org/10.1086/ 379250.
44. Polack FP, Hoffman SJ, Moss WJ, Griffin DE. 2003. Differential effects of priming with DNA vaccines encoding the hemagglutinin and/or fusion proteins on cytokine responses after measles virus challenge. J. Infect. Dis. 187:1794-1800. http://dx.doi.org/10.1086/375245.
45. Good RA, Zak SJ. 1956. Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 18:109-149.
46. Albertyn C, van der Plas H, Hardie D, Candy S, Tomoka T, Leepan EB, Heckmann JM. 2011. Silent casualties from the measles outbreak in South Africa. S. Afr. Med. J. 101:313-317. http://www.samj.org.za/index.php/ samj/article/view/4616/3217.
47. Permar SR, Klumpp SA, Mansfield KG, Kim WK, Gorgone DA, Lifton MA, Williams KC, Schmitz JE, Reimann KA, Axthelm MK, Polack FP, Griffin DE, Letvin NL. 2003. Role of CD8(_) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J. Virol. 77: 4396-4400. http://dx.doi.org/10.1128/JVI.77.7.4396-4400.2003.
48. Permar SR, Klumpp SA, Mansfield KG, Carville AA, Gorgone DA, Lifton MA, Schmitz JE, Reimann KA, Polack FP, Griffin DE, Letvin NL. 2004. Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J. Infect. Dis. 190:998-1005. http:// dx.doi.org/10.1086/422846.
49. Ono N, Tatsuo H, Hidaka Y, Aoki T, Minagawa H, Yanagi Y. 2001. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J. Virol. 75:4399-4401. http://dx.doi.org/10.1128/JVI.75.9.4399-4401.2001.
50. Beauverger P, Buckland R, Wild F. 1993. Establishment and characterisation of murine cells constitutively expressing the fusion, nucleoprotein and matrix proteins of measles virus. J. Virol. Methods 44:199-210. http:// dx.doi.org/10.1016/0166-0934(93)90055-V.
51. Hummel KB, Erdman DD, Heath J, Bellini WJ. 1992. Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays. J. Clin. Microbiol. 30:2874-2880.